Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vupanorsen Phase 1 SAD in Japanese Healthy Adults with Elevated Triglycerides
NCT04459767Phase 1Completed
- Sponsor
- Pfizer
- Start
- Aug 2020
- Primary completion
- Dec 2020
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of vupanorsen in hypertriglyceridemia and dyslipidemia (3 arms), sponsored by Pfizer. Primary endpoints: Incidence of treatment related adverse events, Incidence of abnormal and clinically relevant changes in electrocardiogram and 3 more. Started Aug 2020; status: completed.
02
Drugs
vupanorsen
03
Conditions
hypertriglyceridemiadyslipidemia
Beyond the preview
Go deeper on NCT04459767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04459767.